Studies and our own experience in our clinic over the last 20 years show that dendritic cell therapy (DZT) is extremely successful for prostate carcinoma.
A cure is possible here. In this situation, the goal is to cure the disease and prevent a relapse or recurrence.
Even in patients in stage 4 of the disease, with many metastases, the life expectancy can be extended by a factor of 4 with additional dendritic cell therapy compared to surgery, chemotherapy, and radiotherapy alone. From an average of 2 to 8 years.
As soon as they are diagnosed, people with prostate cancer must quickly decide to have their prostate surgically removed.
Although surgical technology has made great progress in recent years, and even robots now take over the surgeon’s work, serious side effects such as impotence and incontinence remain in most cases (50-70%).
However, no surgical removal of the tumour is also not an alternative.
However, therapy with dendritic cells is most promising when only small amounts of tumour cells are present. Today we know that the immune system often functions much better in patients with a small tumour mass than in patients with a large tumour load.
After NanoKnife, the cancer cells are destroyed and if any have survived, they are so weakened by the electric shocks that it is easy for the dendrites to finish them off.
As with all cancer therapies, the therapy with dendritic cells is more successful the earlier it is started.
The NanoKnife method is the first nerve-sparing prostate cancer treatment. NanoKnife kills the prostate cancer cells instead of removing or irradiating the entire prostate.
MRI is the most accurate method of diagnosing prostate cancer.
If prostate cancer is suspected, usually because of an elevated PSA, a transrectal punch biopsy is recommended, giving a success rate of only 30-35%. This is not good enough for you.
Talk to us and we will introduce you to the world’s leading experts in the use of the Nano Knife and in the treatment of prostate cancer
An MRI-guided and trans perineal 3D mapping, promises a success rate of 85-100% results. Avoid unnecessary invasive procedures.
A standard prostate cancer biopsy can only find cancer if it happens to be in one of the sites examined. If no cancer is found and the PSA level rises again, another biopsy is performed, and so on until the cancer is large enough to be detected or it is detected by chance.
The costs vary depending on the number of electrodes that need to be installed. As a guide, the costs are around EUR 28’000
Combined with a DCT if will be approx. : EUR 44’000